Title Image


Dexlansoprazole DR Capsule
07.Dexlansoprazole DR Capsule
Indication ­ ‒ ­Healing of all grades of erosive esophagitis (EE)
­ ‒ ­Maintaining healing of EE
­­ ‒ ­Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD)
Status  ‒ ­The commercialization partner, Par, received final approval in April 2017.
­ ‒ US Launched in November 2022 by Par Pharmaceutical.
Product Advantages ­ ‒ Settled with the brand company.
­ ‒ Final approval for 30mg and 60mg.
Market Size According to IQVIA data, the total sales of Dexlansoprazole DR Capsule in the US were approximately US$0.453 billion for the first half of 2022.